首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 精神病 > 中樞神經系統的藥物開發：憂鬱症
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

中樞神經系統的藥物開發：憂鬱症

CNS Drug Discoveries: Depression Chapter

出版商 Espicom Business Intelligence
出版日期 2008年08月 商品編碼 47459
內容資訊 英文 Pages: 88
價格
US $ 1040 Hard Copy
US $ 1040 PDF by E-mail (Single user license)
US $ 1040 Web Access (Single user license)


中樞神經系統的藥物開發：憂鬱症 是由出版商Espicom Business Intelligence在2008年08月所出版的。 這份英文市場調查報告書包含Pages: 88 價格從美金1040起跳。

簡介

抗憂鬱症劑市場為中樞神經系統疾病中最大的市場，其2005年的銷售表現達到162億美金。此飽和市場近年來有許多的學名藥陸續加入，並且逐漸地蠶食主要品牌的市場佔有狀況。

以提供醫療儀器、藥品相關資訊而獲全球高度評價的英國市調公司 Espicom Business Intelligence ，彙整憂鬱症治療的藥物開發動向，並出版綜合報告書"CNS Drug Discoveries: Depression Chapter"。

此報告書除了說明憂鬱症的概要與病患動向、各國市場的治療藥銷售動向，也探討主要品牌分析、開發中的新藥等。此報告書的概略架構如下所示。

摘要

背景

  • 何謂憂鬱症、為何對它有興趣呢
  • 病患統計
    • 罹患率、診斷率、治療：當今與未來
  • 病患模式
    • 主要7國市場的病患人口預測（2005年∼2012年）
  • 擴大促進因素
  • 擴大風險•阻礙因素
  • 全球抗憂鬱症劑市場
  • 全球銷售的細目
    • 美國
    • 歐洲
    • 日本及其他各國
    • 2005年及2006年的主要企業與製品
    • 2012年的主要企業與製品
  • 當今治療法
    • 主要品牌
    • 當今製品的專利
  • 主要品牌分析
  • 血清重吸收抑制劑
  • 血清及去甲腎上腺素重吸收抑制劑
  • 去甲腎上腺素及多巴胺重吸收抑制劑
  • 現今治療法在2005年至2012年間的銷售預測
  • 開發中的新藥
  • 第3階段藥劑分析

目錄

Abstract

The market for antidepressive drugs is the largest segment of the CNS sector with global sales of US$16.2 billion in 2005. Find out more in this chapter of CNS Drug Discoveries.

The market for antidepressive drugs is the largest segment of the CNS sector with global sales of US$16.2 billion in 2005, and annual growth of 2% year on year. This is a saturated market where a number of generics have been launched and eroded the market share of leading brands. This chapter focuses on the ways in which companies have optimised the life-cycle of their products through new formulations, combination and new products in order to protect their franchises. It looks at the changing dynamics in the marketplace and evaluates how effective the launch of Cymbalta (Eli Lilly), and Wellbutrin XL (GSK), have been.

It is estimated that depression affects over 18.8 million US citizens and over 121 million people worldwide, with approximately 20% of the global population at risk of developing major depression at some point in their lives. Women are almost twice as likely to suffer from depression as men (9.5% versus 5.8%), but prevalence figures vary from country to country. Depression costs the US economy an estimated US$44 billion each year and the WHO predicts depression will become the leading cause of disability by the year 2020.

Global depression market

The global market for antidepressants is unevenly distributed. In 2005, the US antidepressant market accounted for 66% of the global market compared to 23% in Europe and 11% rest of world (largely Japan).

We believe the depression market is now saturated as numerous formulations, combinations and generics are available. In order for new products to capitalise on this market they will have to demonstrate improvements in the efficacy, speed of onset, safety/tolerability of drugs and a reduction in remission rates and relapse/recurrence.

Table of Contents

DEPRESSION

  • EXECUTIVE SUMMARY
  • THE FACTS
    • What is depression and why are we interested in it?
  • PATIENT STATISTICS
    • Incidence, diagnosis rates and treatment; now and in the future
  • PATIENT MODEL
    • Summary of patient population forecasts in seven major markets (2005A-2012E)
    • Model assumptions
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
  • GLOBAL ANTIDEPRESSANT MARKET
    • Global CNS Market (US$68.7 billion)
  • GLOBAL SALES SPLIT
    • Global sales by region (2005A)
    • US market
      • Antidepressant US drugs sales by (2005A)
    • European market
      • European Antidepressant sales by (2005A)
    • ROW/Japanese market
    • The Major Players Products in 2005 & 2006
      • Market share of Antidepressant players by sales (Dec 2005A)
    • The Major Players and Products in 2012
      • Market share of Antidepressant Players by sales (Dec 2012E)
  • CURRENT TREATMENTS
    • Leading Brands
      • Comparison of leading antidepressant drugs
    • Patent Exposure of Current Products
      • Patent Exposure of Leading Antidepressant Brands
  • ANALYSIS OF LEADING BRANDS
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Lexapro/Cipralex (Forest/Lundbeck)
      • Prozac (Eli Lilly)
      • Zoloft (Pfizer)
    • Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
      • Cymbalta (Eli Lilly)
      • Effexor (Wyeth)
    • Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
      • Wellbutrin (GlaxoSmithKline)
  • GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
    • Sales Forecasts of Current Leading Antidepressant Drugs
    • Model assumptions
  • NEW DRUGS IN R&D
    • Drugs in Development to Treat Depression and Anxiety Related Disorders
  • ANALYSIS OF PHASE III DRUGS
    • New Drugs in Phase III Development to Treat Depression and Anxiety
    • Phase III drugs
    • Other Phase III drugs of interest
Back to Top